Patents by Inventor Dimitris Kalofonos
Dimitris Kalofonos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10464912Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: March 3, 2017Date of Patent: November 5, 2019Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
-
Publication number: 20170174643Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Inventors: Isabel KALOFONOS, G. Patrick STAHLY, William MARTIN-DOYLE, Dimitris KALOFONOS, Travis L. HOUSTON, Jeffrey S. STULTS
-
Patent number: 9611234Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: November 4, 2014Date of Patent: April 4, 2017Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
-
Patent number: 9447056Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: GrantFiled: April 11, 2014Date of Patent: September 20, 2016Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Patent number: 9032215Abstract: Management of access control in wireless networks known as smart spaces includes a framework that presents non-expert users with a consistent and intuitive interaction mechanism to manage access to devices they own in the smart space without exposing to them the complexity of the underlying security infrastructure. Access control of devices in a network can include providing an interface between a user-level tool on a first device connected to a network and security components associated with the network, communicating a passlet between the user-level tool and the interface, verifying access permission at a second device on the network where access permissions are based on the passlet, and providing a response to the first device based on the verification of the access permission in the passlet. The passlet provides access permissions based on a particular user rather than a particular device.Type: GrantFiled: June 15, 2005Date of Patent: May 12, 2015Assignee: Nokia CorporationInventors: Dimitris Kalofonos, Saad Shakhshir
-
Publication number: 20150057319Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: ApplicationFiled: November 4, 2014Publication date: February 26, 2015Inventors: Isabel KALOFONOS, Patrick G. STAHLY, William Martin-Doyle, Dimitris KALOFONOS, Travis L. Houston, Jeffrey S. STULTS
-
Patent number: 8906948Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: September 3, 2009Date of Patent: December 9, 2014Assignee: Bionevia, LLCInventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Patent number: 8868105Abstract: An approach for generating location stamps in response to a request from a device is presented. A location stamping platform receives a request from a device for one or more location stamps. The location stamping platform then processes and/or facilitates a processing of a hierarchy of one or more policies to determine one or more candidate location stamps in response to the request.Type: GrantFiled: October 24, 2011Date of Patent: October 21, 2014Assignee: Nokia CorporationInventors: Dimitris Kalofonos, James Card, Zoe Antoniou, Mark Peterson, Hans Peter Brondmo, Eric Cheng, Jacob Barss-Bailey, Eric Anthony Silva
-
Publication number: 20140221438Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Patent number: 8697735Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: GrantFiled: January 25, 2011Date of Patent: April 15, 2014Assignee: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Patent number: 8639810Abstract: Secure resource discover in peer-to-peer networks involves creating a resource discovery record associated with a computing resource of a user device that is made available via the user device to peers of a peer-to-peer network. The resource discovery record describes the computing resource and may be independent of native service discovery mechanisms of the peer-to-peer network. An access right record is created that controls the ability of one or more contacts to gain access to the resource discovery record. The resource discovery record is sent to the one or more contacts via the peer-to-peer network. The one or more contacts can use the resource discovery record to access the computing resource via the peer-to-peer network in accordance with the access right record.Type: GrantFiled: August 8, 2012Date of Patent: January 28, 2014Assignee: Nokia CorporationInventors: Dimitris Kalofonos, Zoe Antoniou, Franklin Reynolds
-
Publication number: 20130102328Abstract: An approach for generating location stamps in response to a request from a device is presented. A location stamping platform receives a request from a device for one or more location stamps. The location stamping platform then processes and/or facilitates a processing of a hierarchy of one or more policies to determine one or more candidate location stamps in response to the request.Type: ApplicationFiled: October 24, 2011Publication date: April 25, 2013Applicant: Nokia CorporationInventors: Dimitris Kalofonos, James Card, Zoe Antoniou, Mark Peterson, Hans Peter Brondmo, Eric Cheng, Jacob Barss-Bailey, Eric Anthony Silva
-
Publication number: 20120304257Abstract: Secure resource discover in peer-to-peer networks involves creating a resource discovery record associated with a computing resource of a user device that is made available via the user device to peers of a peer-to-peer network. The resource discovery record describes the computing resource and may be independent of native service discovery mechanisms of the peer-to-peer network. An access right record is created that controls the ability of one or more contacts to gain access to the resource discovery record. The resource discovery record is sent to the one or more contacts via the peer-to-peer network. The one or more contacts can use the resource discovery record to access the computing resource via the peer-to-peer network in accordance with the access right record.Type: ApplicationFiled: August 8, 2012Publication date: November 29, 2012Applicant: Nokia CorporationInventors: Dimitris KALOFONOS, Zoe ANTONIOU, Franklin REYNOLDS
-
Patent number: 8271649Abstract: Secure resource discover in peer-to-peer networks involves creating a resource discovery record associated with a computing resource of a user device that is made available via the user device to peers of a peer-to-peer network. The resource discovery record describes the computing resource and may be independent of native service discovery mechanisms of the peer-to-peer network. An access right record is created that controls the ability of one or more contacts to gain access to the resource discovery record. The resource discovery record is sent to the one or more contacts via the peer-to-peer network. The one or more contacts can use the resource discovery record to access the computing resource via the peer-to-peer network in accordance with the access right record.Type: GrantFiled: August 30, 2007Date of Patent: September 18, 2012Assignee: Nokia CorporationInventors: Dimitris Kalofonos, Zoe Antoniou, Franklin Reynolds
-
Publication number: 20120196895Abstract: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: January 11, 2010Publication date: August 2, 2012Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko
-
Publication number: 20110281911Abstract: The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotome conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: August 3, 2009Publication date: November 17, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko, Jeffrey P. Kiplinger
-
Publication number: 20110275681Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: ApplicationFiled: January 25, 2011Publication date: November 10, 2011Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20110275679Abstract: The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal.Type: ApplicationFiled: August 6, 2009Publication date: November 10, 2011Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, Dimitris Kalofonos, Patrick G. Stahly, Jeffrey S. Stults, Jason A. Hanko, Rex A. Shipplett, William Martin-Doyle
-
Publication number: 20110275695Abstract: The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them.Type: ApplicationFiled: June 11, 2009Publication date: November 10, 2011Applicant: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, Dimitris Kalofonos, William Martin-Doyle, Jason Hanko, Eric J. Hagen
-
Publication number: 20110275682Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: ApplicationFiled: September 3, 2009Publication date: November 10, 2011Applicant: BioNevia PhArmaceuticals, Inc.Inventors: Isabel Kalofonos, Patrick G. Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults